Crystalline Amino Lipid Forms for Stable Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The delivery of biologically active substances such as nucleic acids to cells is hindered by their instability and low cell permeability, and existing lipid-containing nanoparticle compositions face challenges in safety, efficacy, and specificity, with physical and chemical properties complicating their use in drug delivery.
Innovation Solution
Development of novel solid crystalline forms of long-chain amino lipids, including salts and cocrystals with specific coformers, which exhibit higher melting points and are non-hygroscopic, allowing for improved handling, stability, and simplified purification and production processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If long-chain amino lipids are used in liquid form, then cell permeability and delivery efficiency are improved, but handling difficulty and storage stability deteriorate
Solution Approach 1:
The patent changes the physical state parameter of amino lipids from liquid to solid crystalline form through controlled crystallization processes. This phase transition enables improved handling and storage stability while maintaining the lipid's biological activity and cell membrane permeability properties needed for drug delivery applications.
Solution Approach 2:
The patent utilizes phase transition from liquid to solid crystalline state to transform the physical properties of amino lipids. The crystallization process creates a solid form that is easier to handle and store, while the patent ensures the lipid retains its functional properties for cellular delivery through controlled phase change methods.
2Reliability
If long-chain amino lipids are used in liquid form, then membrane permeability is maintained, but storage stability and purity deteriorate
Solution Approach 1:
The patent changes the physical state from liquid to solid crystalline form, which significantly improves storage stability by preventing degradation and contamination while maintaining the lipid's membrane permeability function. The crystalline structure provides a more stable composition that preserves purity over time.
Solution Approach 2:
The patent employs temporary crystallization agents or coformers that facilitate the formation of stable crystalline structures during storage, which can be removed or decomposed later, leaving the pure amino lipid in a stable solid form that maintains both storage stability and membrane permeability.
3Manufacturing precision
If conventional lipid purification methods are used, then purity is achieved, but production time and complexity increase
Solution Approach 1:
The patent utilizes crystallization, a phase transition process, to purify amino lipids. By controlling the crystallization conditions, the lipid forms pure crystalline structures that can be separated from impurities through filtration or centrifugation, achieving high purity with reduced production time compared to conventional chromatographic methods.
Solution Approach 2:
The patent changes the physical parameters during purification by controlling temperature, pH, and solvent conditions to induce crystallization. This parameter-based approach enables rapid separation of pure crystalline amino lipid from impurities, significantly reducing production time while maintaining manufacturing precision.
4Productivity
If amino lipids are formulated in conventional nanoparticle compositions, then delivery function is achieved, but safety and specificity are compromised
Solution Approach 1:
The patent creates composite crystalline structures by forming salts or cocrystals of amino lipids with specific coformers. These composite structures enhance the safety profile by reducing cytotoxicity while maintaining delivery function, and improve specificity through controlled crystal structures that optimize lipid interaction with cell membranes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solid forms enhance the handling, stability, and accuracy of amino lipids, facilitating their use in large-scale production and characterization, thereby improving the delivery of biologically active substances to cells.
Implementation Method 1
Development of novel solid crystalline forms of long-chain amino lipids, including salts and cocrystals with specific coformers, which exhibit higher melting points and are non-hygroscopic
Implementation Method 2
which exhibit higher melting points and are non-hygroscopic, allowing for improved handling, stability
Data Source
AI summary
Provided herein are novel solid forms of each of four compounds: (1) heptadecan-9-yl 8-((2-hydroxyethyl)amino)octanoate (“Compound 1”), (2) heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate (“Compound 2”), (3) heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (“Compound 3”), and (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (“MC3”), and related compositions and methods.